Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 15 of 15 matching drugs for PDE5A — including drugs targeting any of its 12 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
dipyridamole, fluorouracil, leucovorin calcium, mitomycin c PDE5A Direct 1
nivolumab, tadalafil, oral vancomycin PDE5A Direct 1
pembrolizumab, tadalafil PDE5A Direct 1
tadalafil PDE5A Direct yes 1
tadalafil, gemcitabine, radiation, pancreaticoduodenectomy PDE5A Direct 1
tadalafil, pembrolizumab, ipilimumab, crs-207 PDE5A Direct 1
e6l PDE5A Direct yes 0
pentoxifylline PDE5A Direct yes 0
sildenafil PDE5A Direct yes 0
sildenafil citrate PDE5A Direct yes 0
unnamed compound PDE5A Direct yes 0
vardenafil hydrochloride PDE5A Direct yes 0
gabapentin, sulfasalazine, memantine, temozolomide, radiotherapy NFKB2 SSL via NFKB2 1
sulfasalazine NFKB2 SSL via NFKB2 1
ataluren RPL22 SSL via RPL22 yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.